Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥110.78 Million ≈ $16.21 Million USD) by net assets (CN¥9.02 Billion ≈ $1.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Tianjin Zhongxin Pharmaceutical Group Co balance sheet liabilities for a breakdown of total debt and financial obligations.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pan African Resources PLC
JSE:PAN
|
0.064x |
|
Jubilant Foodworks Limited
NSE:JUBLFOOD
|
0.403x |
|
F&G Annuities & Life Inc.
NYSE:FG
|
0.312x |
|
Grinm Advanced Materials Co Ltd
SHG:600206
|
-0.092x |
|
SKC Co. Ltd
KO:011790
|
-0.064x |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
-0.045x |
|
Alliance Resource Partners LP
NASDAQ:ARLP
|
0.077x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.145x |
Annual Cash Flow Conversion Efficiency for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2001–2024)
The table below shows the annual cash flow conversion efficiency of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Tianjin Zhongxin Pharmaceutical Group Co.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
CN¥924.67 Million ≈ $135.31 Million |
0.118x | +13.69% |
| 2023-12-31 | CN¥6.65 Billion ≈ $972.41 Million |
CN¥688.49 Million ≈ $100.75 Million |
0.104x | +0.23% |
| 2022-12-31 | CN¥6.55 Billion ≈ $958.76 Million |
CN¥677.25 Million ≈ $99.10 Million |
0.103x | -21.01% |
| 2021-12-31 | CN¥6.51 Billion ≈ $953.18 Million |
CN¥852.40 Million ≈ $124.73 Million |
0.131x | +15.96% |
| 2020-12-31 | CN¥5.95 Billion ≈ $870.66 Million |
CN¥671.42 Million ≈ $98.25 Million |
0.113x | +25.79% |
| 2019-12-31 | CN¥5.52 Billion ≈ $808.22 Million |
CN¥495.49 Million ≈ $72.51 Million |
0.090x | +29.50% |
| 2018-12-31 | CN¥5.05 Billion ≈ $739.62 Million |
CN¥350.14 Million ≈ $51.24 Million |
0.069x | +8165.98% |
| 2017-12-31 | CN¥4.63 Billion ≈ $676.85 Million |
CN¥-3.97 Million ≈ $-581.32K |
-0.001x | -100.88% |
| 2016-12-31 | CN¥4.30 Billion ≈ $629.56 Million |
CN¥419.90 Million ≈ $61.44 Million |
0.098x | +11.12% |
| 2015-12-31 | CN¥4.11 Billion ≈ $600.72 Million |
CN¥360.58 Million ≈ $52.76 Million |
0.088x | -9.77% |
| 2014-12-31 | CN¥2.95 Billion ≈ $431.19 Million |
CN¥286.85 Million ≈ $41.98 Million |
0.097x | +17.45% |
| 2013-12-31 | CN¥2.57 Billion ≈ $376.80 Million |
CN¥213.44 Million ≈ $31.23 Million |
0.083x | +807.71% |
| 2012-12-31 | CN¥2.28 Billion ≈ $333.46 Million |
CN¥20.81 Million ≈ $3.04 Million |
0.009x | -88.42% |
| 2011-12-31 | CN¥2.21 Billion ≈ $322.67 Million |
CN¥173.88 Million ≈ $25.44 Million |
0.079x | +18.36% |
| 2010-12-31 | CN¥2.09 Billion ≈ $305.38 Million |
CN¥139.04 Million ≈ $20.35 Million |
0.067x | +42.83% |
| 2009-12-31 | CN¥1.79 Billion ≈ $261.66 Million |
CN¥83.41 Million ≈ $12.21 Million |
0.047x | -55.90% |
| 2008-12-31 | CN¥1.47 Billion ≈ $215.50 Million |
CN¥155.77 Million ≈ $22.79 Million |
0.106x | +606.94% |
| 2007-12-31 | CN¥1.35 Billion ≈ $196.89 Million |
CN¥20.13 Million ≈ $2.95 Million |
0.015x | +175.03% |
| 2006-12-31 | CN¥1.41 Billion ≈ $206.07 Million |
CN¥-28.08 Million ≈ $-4.11 Million |
-0.020x | -114.84% |
| 2005-12-31 | CN¥1.95 Billion ≈ $285.17 Million |
CN¥261.91 Million ≈ $38.33 Million |
0.134x | +2304.03% |
| 2004-12-31 | CN¥1.88 Billion ≈ $274.74 Million |
CN¥10.50 Million ≈ $1.54 Million |
0.006x | -86.57% |
| 2003-12-31 | CN¥1.84 Billion ≈ $269.08 Million |
CN¥76.57 Million ≈ $11.20 Million |
0.042x | -62.51% |
| 2002-12-31 | CN¥1.69 Billion ≈ $247.19 Million |
CN¥187.60 Million ≈ $27.45 Million |
0.111x | +8.52% |
| 2001-12-31 | CN¥1.54 Billion ≈ $225.52 Million |
CN¥157.73 Million ≈ $23.08 Million |
0.102x | -- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more